Sana Biotechnology has closed its first round at more than $700m after investors including GV swung behind its vision to commercialise cell therapies.
US-based stem cell medicine developer Sana Biotechnology closed its inaugural funding round on Tuesday, having raised more than $700m from investors including GV, a corporate venturing subsidiary of internet technology group Alphabet.
The round also featured F-Prime Capital, a fund owned by investment and financial services group Fidelity, as well as Canada Pension Plan Investment Board, Alaska Permanent Fund and the Public Sector Pension Investment Board.
Baillie Gifford, Arch Venture Partners, Flagship Pioneering, Bezos Expeditions, Omega Funds, Altitude Life Science…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
